M&A Deal Summary

Jazz Pharmaceuticals Acquires GW

On February 3, 2021, Jazz Pharmaceuticals acquired life science company GW for 6.7B USD

Acquisition Highlights
  • This is Jazz Pharmaceuticals’ 6th transaction in the Life Science sector.
  • This is Jazz Pharmaceuticals’ largest (disclosed) transaction.
  • This is Jazz Pharmaceuticals’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-02-03
Target GW
Sector Life Science
Buyer(s) Jazz Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 6.7B USD
Advisor(s) Goldman Sachs
Centerview Partners (Financial)
Cravath, Swaine & Moore
Slaughter and May (Legal)

Target

GW

Cambridge, United Kingdom
GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Jazz Pharmaceuticals

Dublin, Ireland
Category Company
Founded 2003
Sector Life Science
Employees2,800
Revenue 3.8B USD (2023)
DESCRIPTION
Jazz Pharmaceuticals office in Palo Alto, California.
Jazz Pharmaceuticals office in Palo Alto, California.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.

DEAL STATS #
Overall 6 of 6
Sector (Life Science) 6 of 6
Type (Add-on Acquisition) 6 of 6
Country (United Kingdom) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-08-12 Cavion

Charlottesville, Virginia, United States

Cavion, Inc. is a clinical-stage biotechnology company. Cavion's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures. Cavion, Inc. was founded in 2006 and is based in Charlottesville, Virginia.

Buy $313M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-28 Jazz Pharmaceuticals - Sunosi

Dublin, Ireland

Jazz Pharmaceuticals' Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Sell $53M
Mergr

Product

Company

Legal